WarrenDavidShlomchikMD

Hematologic Oncology

Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine

Dr. Shlomchik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1993 - 1997
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989

PubMed

Maintenance strategies for relapse prevention and treatment.
Emily Geramita, Jing-Zhou Hou, Warren D Shlomchik, Sawa Ito
Hematology. American Society of Hematology. Education Program. 2024-12-06
Chemokine receptors are required for effector T cell trafficking to GVHD tissues but not to bone marrow.
Kai Zhao, Jieqing Zhu, Sarah Theresa Rosenberger, Meng Zhou, Warren David Shlomchik
Blood Advances. 2024-08-21
Natalizumab for GVHD: too little or too late?
Kevin Quann, Faruk Sacirbegovic, Warren D Shlomchik
Blood Advances. 2023-09-12

Lectures

The Making of Memory
60th American Society of Hematology Annual Meeting - 12/1/2018
CD8+ Effector T Cell Migration into the Bone Marrow of Transplanted Mice: Influence of Gvhd, Leukemia Cells and Variable Dependence on Chemokine Receptors
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Novel Transplant Approach Improves the Odds for Leukemia PatientsJanuary 10th, 2022

Leukemia Stem Cells: Essential Targets For GVL And Mediators Of Gvl-ResistanceNational Cancer Institute2009–2012
Role Of Tissue Antigen Presenting Cells In GVHDNational Heart, Lung, And Blood Institute2011
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2010
Dendritic Cell Subsets And Paths Of Maturation In Graft-Vs.-Host Disease (GVHD)National Heart, Lung, And Blood Institute2007–2010
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2006–2009
Graft Versus Leukemia Against Murine Chronic Phase &Blast Crisis CMLNational Cancer Institute2007
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Heart, Lung, And Blood Institute2006
GVL Against Murine Chronic Phase And Blast Crisis CMLNational Cancer Institute2003–2006
Novel Immunotoxins For Depletion Of Dendritic CellsNational Heart, Lung, And Blood Institute2005
Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1999–2002
Pathogenic Mechanisms Of GVD In Murine ModelNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000
Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1998